Galapagos NV
AEX:GLPG

Watchlist Manager
Galapagos NV Logo
Galapagos NV
AEX:GLPG
Watchlist
Price: 25.84 EUR -0.84% Market Closed
Market Cap: 1.7B EUR
Have any thoughts about
Galapagos NV?
Write Note

Galapagos NV
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Galapagos NV
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Galapagos NV
AEX:GLPG
Change in Working Capital
-€489.6m
CAGR 3-Years
-17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Change in Working Capital
-$4.8m
CAGR 3-Years
N/A
CAGR 5-Years
-83%
CAGR 10-Years
-2%
Oxurion NV
XBRU:OXUR
Change in Working Capital
€1.6m
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Celyad Oncology SA
XBRU:CYAD
Change in Working Capital
-€2.9m
CAGR 3-Years
-66%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Galapagos NV
Glance View

Market Cap
1.7B EUR
Industry
Biotechnology

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 1,309 full-time employees. The company went IPO on 2005-05-06. The firm is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

GLPG Intrinsic Value
28.4 EUR
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Galapagos NV's Change in Working Capital?
Change in Working Capital
-489.6m EUR

Based on the financial report for Sep 30, 2024, Galapagos NV's Change in Working Capital amounts to -489.6m EUR.

What is Galapagos NV's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
-17%

Over the last year, the Change in Working Capital growth was -11%. The average annual Change in Working Capital growth rates for Galapagos NV have been -17% over the past three years .

Back to Top